Fully Online Care
In-House RxDose Adjustments By Provider
Prescription IncludedYes
Telehealth IncludedYes
Online-Only OptionYes
Skip LabsNot Disclosed
- Top 25 lowest monthly cost · Flat-rate pricing · All-inclusive pricing
- No commitment required
- 100% online · Free consultation
- Multiple pharmacy options · Third-party tested
- Free expedited shipping · Supplies included · Discreet packaging
- Tirzepatide, Semaglutide
- Available in all 50 states with some pharmacy restrictions
- Auto-renewing plans · Cancellation terms apply
- Video visit in some cases
- Mixed additive-free options
- Weak customer reviews
Provider Plans
Monthly Plan
TirzepatideMonthly
$149/avg
PharmacyRed Rock (503A)
Precision Medicine (503A)
Third-Party Tested
AdditivesB12 Or Glycine
At Red Rock
PreservativeBenzyl Alcohol
At Red Rock
BUD (Shelf Life)90 Days
At Red Rock
BillingMonthly
CommitmentNo Commitment
Other FeesNo Extra Fees
Auto-RenewsYes
| DoseYour Supply | Your Price | Your Supply | Avg/mo | Your Value |
|---|---|---|---|---|
| 2.5mg/wk10mg/mo | $149.00 | 10mg | $149 | $14.90/mg |
| 5.0mg/wk20mg/mo | $149.00 | 20mg | $149 | $7.45/mg |
| 7.5mg/wk30mg/mo | $149.00 | 30mg | $149 | $4.97/mg |
| 10.0mg/wk40mg/mo | $149.00 | 40mg | $149 | $3.73/mg |
| 12.5mg/wk50mg/mo | $149.00 | 50mg | $149 | $2.98/mg |
| 15.0mg/wk60mg/mo | $149.00 | 60mg | $149 | $2.48/mg |
States Excluded By Pharmacy
Red Rock (503A)AR
Precision Medicine (503A)None
Provider Details
Self-Pay
Credit
Insurance AcceptedNo
HSA/FSA AcceptedNot Disclosed
Financing AvailableNot Disclosed
LegitScript Certified
Weak Customer Reviews125,000+ Patients
LegitScript CertifiedYes
HIPAA CompliantYes
Free Express Shipping
Supplies Included
Free ShippingYes
Expedited ShippingYes
Discreet PackagingYes
Tirz + Sema · 503A
Format: Injection
Offers TirzepatideYes
Offers SemaglutideYes
Offers BrandNo
Other TreatmentsYes
Contact & Support
Live Chat24/7
Emailcare@trinitymeds.com
Phone(253) 650-6969
Address7950 NW 53rd Street, Suite 337, Doral, FL
Websitehttps://www.trinitymeds.com
Provider Notes
Compliance
The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.